Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout
about
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsAllopurinol: insights from studies of dose-response relationships.ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approachesImpact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsKnowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practiceAdvances in pharmacotherapy for the treatment of gout.Pharmacogenetic considerations in the treatment of gout.Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trail protocolChinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.Pilot study of a multidisciplinary gout patient education and monitoring program.Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout
P2860
Q26738948-C5CAB09A-5632-42C3-AB62-8CD8A9695C96Q30240163-E6C55626-01F0-43AD-81ED-18F690CE09A2Q33602553-EE67EB77-5568-4D4D-8674-877575A13033Q33864537-2A03B439-B303-4244-93E9-1203F64E449EQ37124476-1380C6AE-5E93-4037-809B-2346FEEFC036Q38303416-DD075B7D-341D-445D-BA7C-483722C5AABBQ38422218-9D647AC1-E36F-4822-88E1-4275C5DED9DFQ42650070-3612BE26-099C-468E-8A06-76FE7BF52513Q45025526-63F06D42-198F-4248-8C6D-8CBCF043AB15Q47104100-FB1260CF-E68A-4D93-BCF6-F559B3FE2178Q48098788-A1D79F5D-108E-46E9-ACDE-FFD9C0F9067CQ50111167-85C59D2D-6CE2-4042-97F5-FE552A2F8229Q51736512-970540D3-EDFF-4311-8012-14801132A3CBQ53815600-1C0AF648-31C9-4B06-8202-CCDDEB0362A8Q56637250-74C43BA1-FBA9-4122-BF8B-16B5BDBC2976Q57154626-3FF796D7-2655-41B4-B0AD-DF813A5ED7E7
P2860
Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impaired response or insuffici ...... rinol in the treatment of gout
@ast
Impaired response or insuffici ...... rinol in the treatment of gout
@en
Impaired response or insuffici ...... rinol in the treatment of gout
@nl
type
label
Impaired response or insuffici ...... rinol in the treatment of gout
@ast
Impaired response or insuffici ...... rinol in the treatment of gout
@en
Impaired response or insuffici ...... rinol in the treatment of gout
@nl
prefLabel
Impaired response or insuffici ...... rinol in the treatment of gout
@ast
Impaired response or insuffici ...... rinol in the treatment of gout
@en
Impaired response or insuffici ...... rinol in the treatment of gout
@nl
P2093
P2860
P50
P1476
Impaired response or insuffici ...... rinol in the treatment of gout
@en
P2093
Daniel F B Wright
Lisa K Stamp
Rebecca L Roberts
P2860
P304
P356
10.1016/J.SEMARTHRIT.2014.05.007
P577
2014-05-09T00:00:00Z